{"id":"travoprost-timolol-fixed-combination-travoprost","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Conjunctival hyperemia"},{"rate":"10-20","effect":"Eye irritation/discomfort"},{"rate":"5-15","effect":"Increased iris pigmentation"},{"rate":"5-10","effect":"Eyelash growth"},{"rate":null,"effect":"Bradycardia"},{"rate":null,"effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL1200799","moleculeType":"Small molecule","molecularWeight":"500.55"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Travoprost binds to prostaglandin F (FP) receptors on the ciliary muscle and trabecular meshwork, enhancing drainage of aqueous humor through the uveoscleral pathway. Timolol blocks beta-adrenergic receptors in the ciliary body, reducing aqueous humor secretion. The combination provides complementary mechanisms to lower intraocular pressure more effectively than either agent alone.","oneSentence":"Travoprost is a prostaglandin F analog that increases uveoscleral outflow of aqueous humor, while timolol is a non-selective beta-blocker that decreases aqueous humor production, together reducing intraocular pressure.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:13:59.641Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Open-angle glaucoma"},{"name":"Ocular hypertension"}]},"trialDetails":[{"nctId":"NCT04828057","phase":"","title":"Preservative-free Fixed-dose Combination of Tafluprost 0.0015% / Timolol 0.5% in Patients With Open-angle Glaucoma or Ocular Hypertension: Clinical Effectiveness, Tolerability and Safety in a Real World Setting","status":"COMPLETED","sponsor":"Santen Pharmaceutical (Taiwan) Co., LTD","startDate":"2021-09-01","conditions":"Ocular Surface Disease, Primary Open Angle Glaucoma","enrollment":50},{"nctId":"NCT00757835","phase":"PHASE4","title":"24-hr IOP With Travoprost/Timolol Compared With Latanoprost/Timolol in XFG","status":"COMPLETED","sponsor":"Aristotle University Of Thessaloniki","startDate":"2008-05","conditions":"Glaucoma","enrollment":40},{"nctId":"NCT00981786","phase":"PHASE4","title":"24-Hour Intraocular Pressure With Brinzolamide/Timolol Versus Brimonidine/Timolol","status":"COMPLETED","sponsor":"Aristotle University Of Thessaloniki","startDate":"2009-08","conditions":"Glaucoma","enrollment":51},{"nctId":"NCT03966560","phase":"PHASE4","title":"Choroidal Thickness and Its Correlations With Ocular Parameters in Primary Open-angle Glaucoma","status":"COMPLETED","sponsor":"Afyon Kocatepe University Hospital","startDate":"2014-01","conditions":"Glaucoma, Open-Angle","enrollment":96},{"nctId":"NCT00759239","phase":"PHASE4","title":"Phase IV Randomised Double-masked Clinical Trial: Assessing Morning Versus Evening Dosing of a Fixed Dose Combination of Travoprost 0.004% / Timolol Maleate 0.5% in Patients With Primary Open-angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2008-09","conditions":"Open-angle Glaucoma, Ocular Hypertension","enrollment":36},{"nctId":"NCT01230736","phase":"PHASE4","title":"Safety and Efficacy of Changing to DuoTrav From Prior Therapy","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2010-10","conditions":"Glaucoma","enrollment":105},{"nctId":"NCT00519753","phase":"PHASE4","title":"Success of Transitioning Uncontrolled Glaucoma Patients From Prior Mono or Adjunctive Therapy to DuoTrav","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2007-08","conditions":"Glaucoma","enrollment":522},{"nctId":"NCT00382226","phase":"PHASE4","title":"IOP-Lowering Efficacy of Brinzolamide 1.0% Added to Travoprost 0.004%/Timolol 0.5% Fixed Combination as Adjunctive Therapy","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2006-09","conditions":"Glaucoma","enrollment":195},{"nctId":"NCT02003391","phase":"PHASE4","title":"Efficacy of Travoprost/Timolol for Uncontrolled Intraocular Pressure","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2013-12","conditions":"Open Angle Glaucoma, Ocular Hypertension","enrollment":157},{"nctId":"NCT00887029","phase":"PHASE4","title":"A 12 Week Comparison of DuoTrav and Xalacom in Open-Angle Glaucoma","status":"COMPLETED","sponsor":"Ophthalmic Consultants Centres, Canada","startDate":"2009-01","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":54},{"nctId":"NCT01514721","phase":"PHASE4","title":"Efficacy of Changing to DuoTrav® (Travoprost 0.004%/Timolol 0.5% BAK-Free Fixed Combination) From Prior Therapy","status":"TERMINATED","sponsor":"Alcon Research","startDate":"2012-06","conditions":"Glaucoma","enrollment":37},{"nctId":"NCT00928590","phase":"PHASE3","title":"Safety Study of DuoTrav APS in Patients With Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2009-07","conditions":"Open-angle Glaucoma, Ocular Hypertension","enrollment":155},{"nctId":"NCT01263444","phase":"PHASE4","title":"Safety and Efficacy of Adding AZARGA® Adjunctive to Prostaglandin Therapy","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2011-03","conditions":"Glaucoma, Ocular Hypertension","enrollment":47},{"nctId":"NCT00444184","phase":"PHASE4","title":"24-hour Intraocular Pressure Control With Travoprost/Timolol Fixed Combination Versus Travoprost","status":"COMPLETED","sponsor":"Aristotle University Of Thessaloniki","startDate":"2007-03","conditions":"Glaucoma","enrollment":32},{"nctId":"NCT00331240","phase":"PHASE3","title":"24-Hour Intraocular Pressure (IOP) Control With Travoprost/Timolol Fixed Combination","status":"COMPLETED","sponsor":"Aristotle University Of Thessaloniki","startDate":"2006-03","conditions":"Primary Open Angle Glaucoma, Exfoliation Syndrome","enrollment":32},{"nctId":"NCT01779284","phase":"PHASE4","title":"Travoprost/Timolol vs Latanoprost/Timolol Fixed Combination Therapy","status":"COMPLETED","sponsor":"Aristotle University Of Thessaloniki","startDate":"2012-01","conditions":"Glaucoma","enrollment":42},{"nctId":"NCT01327599","phase":"PHASE4","title":"Efficacy of Changing to DUOTRAV® From Prior Therapy","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2011-08","conditions":"Open-Angle Glaucoma, Ocular Hypertension, Pigment Dispersion Glaucoma","enrollment":60},{"nctId":"NCT01978015","phase":"PHASE4","title":"Blood-aqueous Barrier Changes After the Use of Timolol and Prostaglandin Analogues Fixed Combination in Pseudophakic Patients With POAG","status":"COMPLETED","sponsor":"University of Campinas, Brazil","startDate":"2011-10","conditions":"Uveitis, Anterior, Cystoid Macular Edema","enrollment":69},{"nctId":"NCT01336569","phase":"PHASE4","title":"Safety and Efficacy of Changing to DuoTrav in Patients Uncontrolled on Timolol","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2011-02","conditions":"Glaucoma","enrollment":50},{"nctId":"NCT01696383","phase":"PHASE4","title":"Assessing the Efficacy of DuoTrav as a Replacement Therapy in Glaucoma Patients in Russia","status":"WITHDRAWN","sponsor":"Alcon Research","startDate":"2013-02","conditions":"Glaucoma, Ocular Hypertension","enrollment":""},{"nctId":"NCT01510132","phase":"PHASE4","title":"Travacom Post Marketing Surveillance Study","status":"WITHDRAWN","sponsor":"Alcon Research","startDate":"2012-01","conditions":"Open-angle Glaucoma, Ocular Hypertension","enrollment":""},{"nctId":"NCT01655758","phase":"PHASE4","title":"24-hour Control of Intraocular Pressure (IOP) in Ocular Hypertension","status":"COMPLETED","sponsor":"University of Parma","startDate":"2002-01","conditions":"Ocular Hypertension","enrollment":61},{"nctId":"NCT00767481","phase":"PHASE3","title":"1 Year Study Trav/Brinz QD Fixed Combination Versus COSOPT","status":"TERMINATED","sponsor":"Alcon Research","startDate":"2008-10","conditions":"Glaucoma, Ocular Hypertension","enrollment":6},{"nctId":"NCT00508469","phase":"PHASE4","title":"Adherence Assessment With Travalert Dosing Aid","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2007-10","conditions":"Open-angle Glaucoma, Ocular Hypertension","enrollment":102},{"nctId":"NCT00676637","phase":"","title":"Glaucoma Adherence Study","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2008-05","conditions":"Ocular Hypertension, Primary Open Angle Glaucoma","enrollment":55},{"nctId":"NCT00680329","phase":"","title":"Glaucoma Adherence Study, Spain","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2008-05","conditions":"Ocular Hypertension, Primary Open Angle Glaucoma","enrollment":55},{"nctId":"NCT01542710","phase":"NA","title":"Bimatoprost/Timolol Versus Travoprost/Timolol","status":"COMPLETED","sponsor":"Kasr El Aini Hospital","startDate":"2011-01","conditions":"Glaucoma","enrollment":80},{"nctId":"NCT01168414","phase":"PHASE3","title":"A Study of Ganfort Versus Duotrav in Patients With Primary Open Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Ministry of Health, Malaysia","startDate":"2010-08","conditions":"Ocular Hypertension, Primary Open Angle Glaucoma","enrollment":42},{"nctId":"NCT00471380","phase":"PHASE4","title":"A Phase IV Study of Travoprost + Brinzolamide to Treat Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2007-03","conditions":"Glaucoma, Ocular Hypertension","enrollment":46}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":12,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Travoprost/timolol fixed combination, travoprost","genericName":"Travoprost/timolol fixed combination, travoprost","companyName":"Aristotle University Of Thessaloniki","companyId":"aristotle-university-of-thessaloniki","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Travoprost is a prostaglandin F analog that increases uveoscleral outflow of aqueous humor, while timolol is a non-selective beta-blocker that decreases aqueous humor production, together reducing intraocular pressure. Used for Open-angle glaucoma, Ocular hypertension.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}